H. Lundbeck (OTCPK:HLUYY)
(LUN.CO) has not been my most popular call, partly due to the company's
own issues with launching drugs like Brintellix and Abilify Maintena
against well-established rivals, but also partly due to its relative
obscurity in the U.S. Nevertheless, the shares are up about 25% since my last piece (in a pretty terrible market), and up more than 50% from my initial piece - and that's not too shabby relative to other drug companies over that time.
I'm
starting to think, though, that it may be time to call it a day and
take some profits. I do believe new CEO Kare Schultz can do a lot of
good things for this company, and I do also believe that Brintellix,
Abilify Maintena, and Rexulti still have the opportunity to outperform. I
also believe that the company's Alzheimer's platform is comparatively
undervalued and could surprise to the good. That said, the shares are
now above my "as is" fair value, and I don't feel too comfortable owning
any company largely on the basis of upside potential in Alzheimer's (a
notoriously difficult disease for drug development).
Read more here:
Should Investors Push Their Luck With Lundbeck?
No comments:
Post a Comment